Back to Authors

Hickman, Ingrid J

0000-0003-3205-9165

Mayo Clinic

Department of Nutrition and Dietetics, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

Citations 3

A global action agenda for turning the tide on fatty liver disease
Lazarus, Jeffrey V. , Mark, Henry E. , Allen, Alina M. , Arab, Juan Pablo , Carrieri, Patrizia , Noureddin, Mazen , Alazawi, William , Alkhouri, Naim , Alqahtani, Saleh A. , Anstee, Quentin M. , Brennan, Paul , Burra, Patrizia , Castro‐Narro, Graciela , Cortez‐Pinto, Helena , Cusi, Kenneth , Dedes, Nikos, Duseja, Ajay , Gastaldelli, Amalia , Hagström, Hannes , Huang, Terry T.‐K. , Ivancovsky‐Wajcman, Dana , Kautz, Achim, Kopka, Christopher J. , Krag, Aleksander , Newsome, Philip N. , Rinella, Mary E. , Silva, Marcelo , Tsochatzis, Emmanuel , Valenti, Luca , Zelber‐Sagi, Shira , Schattenberg, Jörn M. , Younossi, Zobair M. , Collaborators, on behalf of the Healthy Livers, Healthy Lives, Adams, Leon A. , Wong, Robert J. , Satapathy, Sanjaya K. , Alves‐Bezerra, Michele , Khader, Yousef , Graupera, Isabel , Grønbæk, Henning , Yılmaz, Yusuf , Thiele, Maja , Lazo, Mariana , Hickman, Ingrid J. , Idılman, Ramazan , Kim, Seung Up , Desalegn, Hailemichael , Oliveira, Cláudia P. , Crespo, Javier , Velasco, J.A. Velarde-Ruiz , Goossens, Nicolas , George, Jacob , George, Jacob , Caussy, Cyrielle , Alswat, Khalid , Bataller, Ramon A , Berg, Thomas , Brennan, Paul N , Castro-Narro, Graciela E , Cortez-Pinto, Helena , Duseja, Ajay , Francque, Sven M , Gastaldelli, Amalia , Hagström, Hannes , Huang, Terry T K , Ivancovsky Wajcman, Dana , Kopka, Christopher J , Krag, Aleksander , Newsome, Philip N , Romero, Diana , Sarin, Shiv Kumar , Terrault, Norah , Tsochatzis, Emmanuel A , Valenti, Luca , Schattenberg, Jörn M , Wong, Vincent Wai-Sun , Sathapathy, Sanjaya , Arab, Juan P , Lazarus, Jeffrey V , Wong, Robert J , Allen, Alina M , Anstee, Quentin M , Hickman, Ingrid J , Rinella, Mary , Yilmaz, Yusuf , Thiele, Maja , Lazo, Mariana , Crespo, Javier , Carrieri, Patrizia , Idilman, Ramazan , Goossens, Nicolas , Velarde-Ruiz Velasco, José Antonio , Desalgn, Hailemicheal , George, Jacob , Arrese, Marco , Francque, Sven , Spearman, C Wendy , Terrault, Norah A. , Villota‐Rivas, Marcela , Wong, Vincent Wai‐Sun , Collaborators, on behalf of the Healthy Livers, Healthy Lives

Hepatology | August 4, 2023 | Volume: 79 | Issue: 2 | Pages: 502-523

10.1097/hep.0000000000000545 Get It

Background and Aims: Fatty liver disease is a major public health threat due to its very high prevalence and related morbidity and mortality. Focused and dedicated interventions are urgently needed to target disease prevention, treatment, and care. Approach and Results: We developed an aligned, prioritized action agenda for the global fatty liver disease community of practice. Following a Delphi methodology over 2 rounds, a large panel (R1 n = 344, R2 n = 288) reviewed the action priorities using Qualtrics XM, indicating agreement using a 4-point Likert-scale and providing written feedback. Priorities were revised between rounds, and in R2, panelists also ranked the priorities within 6 domains: epidemiology, treatment and care, models of care, education and awareness, patient and community perspectives, and leadership and public health policy. The consensus fatty liver disease action agenda encompasses 29 priorities. In R2, the mean percentage of “agree” responses was 82.4%, with all individual priorities having at least a super-majority of agreement (> 66.7% “agree”). The highest-ranked action priorities included collaboration between liver specialists and primary care doctors on early diagnosis, action to address the needs of people living with multiple morbidities, and the incorporation of fatty liver disease into relevant non-communicable disease strategies and guidance. Conclusions: This consensus-driven multidisciplinary fatty liver disease action agenda developed by care providers, clinical researchers, and public health and policy experts provides a path to reduce the prevalence of fatty liver disease and improve health outcomes. To implement this agenda, concerted efforts will be needed at the global, regional, and national levels.
Physical Activity and Nonalcoholic Fatty Liver Disease: A Roundtable Statement from the American College of Sports Medicine
Sallis, Robert E. , Duarte‐Rojo, Andrés , Hallsworth, Kate , Hickman, Ingrid J. , Pugh, Christopher J. A. , SIMON, TRACEY L., Hallsworth, Kate , Hickman, Ingrid J , Duarte-Rojo, Andres , Stine, Jonathan G. , Long, Michelle T. , Corey, Kathleen E. , Allen, Alina M. , Armstrong, Matthew J. , Conroy, David E. , Cuthbertson, Daniel James , Kappus, Matthew R. , Keating, Shelley E , Rotman, Yaron , Simon, Tracey G. , Vilar‐Gómez, Eduardo , Wong, Vincent Wai‐Sun , Schmitz, Kathryn H.

Medicine & Science in Sports & Exercise | May 1, 2023 | Volume: 55 | Issue: 9 | Pages: 1717-1726

10.1249/mss.0000000000003199 Get It

ABSTRACT Although physical activity (PA) is crucial in the prevention and clinical management of nonalcoholic fatty liver disease, most individuals with this chronic disease are inactive and do not achieve recommended amounts of PA. There is a robust and consistent body of evidence highlighting the benefit of participating in regular PA, including a reduction in liver fat and improvement in body composition, cardiorespiratory fitness, vascular biology, and health-related quality of life. Importantly, the benefits of regular PA can be seen without clinically significant weight loss. At least 150 min of moderate or 75 min of vigorous intensity PA are recommended weekly for all patients with nonalcoholic fatty liver disease, including those with compensated cirrhosis. If a formal exercise training program is prescribed, aerobic exercise with the addition of resistance training is preferred. In this roundtable document, the benefits of PA are discussed, along with recommendations for 1) PA assessment and screening; 2) how best to advise, counsel, and prescribe regular PA; and 3) when to refer to an exercise specialist.
American College of Sports Medicine (ACSM) International Multidisciplinary Roundtable report on physical activity and nonalcoholic fatty liver disease
Stine, Jonathan G. , Long, Michelle T. , Corey, Kathleen E. , Sallis, Robert E. , Allen, Alina M. , Armstrong, Matthew J. , Conroy, David E. , Duarte‐Rojo, Andrés , Hallsworth, Kate , Hickman, Ingrid J. , Pugh, Christopher J. A. , Simon, Tracey G. , Hallsworth, Kate , Hickman, Ingrid J , Kappus, Matthew R , Keating, Shelley E , Rotman, Yaron , Vilar-Gomez, Eduardo , Wong, Vincent Wai-Sun , Schmitz, Kathryn H , Long, Michelle T , Allen, Alina M , Corey, Kathleen , Duarte-Rojo, Andres , Cuthbertson, Daniel James , Kappus, Matthew R. , Rotman, Yaron , Vilar‐Gómez, Eduardo , Wong, Vincent Wai‐Sun , Schmitz, Kathryn H.

Hepatology Communications | March 30, 2023 | Volume: 7 | Issue: 4 | Pages: No page available

10.1097/hc9.0000000000000108 Get It

Background and Aims: We present findings from the inaugural American College of Sports Medicine (ACSM) International Multidisciplinary Roundtable, which was convened to evaluate the evidence for physical activity as a means of preventing or modifying the course of NAFLD. Approach and Results: A scoping review was conducted to map the scientific literature and identify key concepts, research gaps, and evidence available to inform clinical practice, policymaking, and research. The scientific evidence demonstrated regular physical activity is associated with decreased risk of NAFLD development. Low physical activity is associated with a greater risk for disease progression and extrahepatic cancer. During routine health care visits, all patients with NAFLD should be screened for and counseled about physical activity benefits, including reduction in liver fat and improvement in body composition, fitness, and quality of life. While most physical activity benefits occur without clinically significant weight loss, evidence remains limited regarding the association between physical activity and liver fibrosis. At least 150 min/wk of moderate or 75 min/wk of vigorous-intensity physical activity are recommended for all patients with NAFLD. If a formal exercise training program is prescribed, aerobic exercise with the addition of resistance training is preferred. Conclusions: The panel found consistent and compelling evidence that regular physical activity plays an important role in preventing NAFLD and improving intermediate clinical outcomes. Health care, fitness, and public health professionals are strongly encouraged to disseminate the information in this report. Future research should prioritize determining optimal strategies for promoting physical activity among individuals at risk and in those already diagnosed with NAFLD.